Development of the CK‐MB‐1 trastuzumab‐resistant HER2‐positive breast cancer cell line and xenograft animal models-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Development of the CK‐MB‐1 trastuzumab‐resistant HER2‐positive breast cancer cell line and xenograft animal models

Published:2021-03-05 Issue:7 Volume:10 Page:2370-2379
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Chung Wei‐Pang¹²³^ORCID,Huang Wei‐Lun³,Liao Wei‐An⁴,Huang Wan‐Ling³,Liu You‐Yu³,Su Wu‐Chou²³

Affiliation:

1. Institute of Clinical Medicine College of Medicine National Cheng Kung University Tainan Taiwan

2. Department of Oncology National Cheng Kung University Hospital College of Medicine National Cheng Kung University Tainan Taiwan

3. Center of Applied Nanomedicine National Cheng Kung University Tainan Taiwan

4. Department of Pathology National Cheng Kung University Hospital College of Medicine National Cheng Kung University Tainan Taiwan

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.3824

Reference29 articles.

1. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer

2. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

3. Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer

4. Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

5. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP